

# Promising results from MiNA Therapeutics on treating Liver Cancer, as CSO is set to speak at RNA Therapeutics 2019

*Chief Scientific Officer of MiNA Therapeutics set to speak at RNA Therapeutics 2019, following MiNA Therapeutics' successful liver cancer therapy news.*

LONDON, LONDON, UNITED KINGDOM, December 14, 2018 /EINPresswire.com/ -- The field of RNA therapeutics has seen rapid development as RNA drugs are now being utilised for personalised medicines and immunotherapy, and to address genetic, infectious and chronic diseases.

Next year's [10th annual conference on RNA Therapeutics](#), taking place in

London on 20th – 21st February 2019, is set to address the latest advancements and challenges in the industry as a host of scientific pioneers and senior experts gather in London to share their extensive knowledge and expertise in the field.

In recent news, pioneer in RNA activation therapeutics MiNA Therapeutics recently announced their positive findings from MTL-CEBPA clinical trial in patients with advanced liver cancer.

The British biotech reported observations of tumour responses in patients when administered liver cancer therapies after treatment with MTL-CEBPA, even reporting complete responses in two patients, supporting evidence that RNA treatment can enhance liver cancer patients' response to standard cancer therapies.\*

The encouraging results of the trial are one of the many developments contributing to the exciting advances in RNA therapy, as after a long time in development, RNA therapies are finally beginning to enter the market.



RNA Therapeutics 2019

MiNA Therapeutics' Chief Scientific Officer, David Blakey, is set to give a keynote presentation at next year's RNA Therapeutics conference in London, where he will discuss "Small Activating RNA – From bench to bedside" and expand on the clinical trial, as well as explore in detail novel MOA of small activating RNAs to upregulate gene expression, preclinical studies demonstrating MOA and therapeutic activity, and clinical experience with MTL-CEBPA – the first saRNA in the clinic.

Delegates will also have the opportunity of hearing from the CEO of biotech Exicure; David Giljohann, who will be speaking about the therapeutic applications of spherical nucleic acids (SNAs) "Spherical Nucleic Acids: Clinical Progress".

David will be concentrating on how localization to endosome permits large numbers of SNA's to be delivered with low toxicity, how SNAs can be used to knockdown genes of interest, or activate immune pathways productively, as well as AST-008 TLR9 agonist clinical trial progress, and XCUR-17 topical antisense in psoriasis.

Attendees will have the chance to explore the advantages of delivery via SNAs, a nano particle-based therapeutic with benefits including entry independent of transfection agents, resistance to degradation, and ability to cross biological barriers.

In addition, with [7+ hours of networking included](#), there will be multiple opportunities for participants to interact with key industry leaders, including Sanofi, Exicure, Roche, MHRA, The RNA Institute, GSK, AstraZeneca, ProQR, and many more.

The event brochure containing the full agenda and speaker line-up, as well as other exclusive content is available to download on the website: <http://www.therapeutics-rna.com/einpr>

10th RNA Therapeutics Conference  
20th – 21st February 2019  
London, UK

\*Labiotech.eu

---END---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Maria Mandic  
SMi Group  
+442078276124  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/471121297>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.